Agomelatine: Clinical experience and adherence to EMA

Hdl Handle:
http://hdl.handle.net/10147/270476
Title:
Agomelatine: Clinical experience and adherence to EMA
Authors:
Sinnott, C; Morris, M
Publisher:
Irish Medical Journal
Journal:
Irish Medical Journal
Issue Date:
Feb-2013
URI:
http://hdl.handle.net/10147/270476
Abstract:
In 2009, the European Medicines Agency (EMA) granted marketing authorisation for the novel antidepressant agomelatine, with the recommendation that liver function tests (LFTs) are checked before, and 6, 12 and 24 weeks after, commencing the drug. This paper describes early clinical experience with agomelatine and audits physician adherence to EMA recommendations. A retrospective review of patients attending general adult psychiatry services in Carlow /Kilkenny (catchment population 120,000) over one year was performed. 62 patients were prescribed agomelatine. 32 patients (52%) had unipolar depression, and 43 (73%) were already established on antidepressant medication. 60 patients (97%) had LFTs measured before starting treatment with agomelatine, but half of patients (47%) did not have further LFTs as recommended. To increase adherence to EMA recommendations and ensure optimal patient safety, existing barriers to effective monitoring must be addressed.
Item Type:
Article
Language:
en
Keywords:
PSYCHIATRY; MENTAL HEALTH; MEDICATION MANAGEMENT
Local subject classification:
ANTIDEPRESSANTS; AGOMELATINE; MEDICATION ADHERENCE

Full metadata record

DC FieldValue Language
dc.contributor.authorSinnott, Cen_GB
dc.contributor.authorMorris, Men_GB
dc.date.accessioned2013-02-26T12:18:05Z-
dc.date.available2013-02-26T12:18:05Z-
dc.date.issued2013-02-
dc.identifier.urihttp://hdl.handle.net/10147/270476-
dc.description.abstractIn 2009, the European Medicines Agency (EMA) granted marketing authorisation for the novel antidepressant agomelatine, with the recommendation that liver function tests (LFTs) are checked before, and 6, 12 and 24 weeks after, commencing the drug. This paper describes early clinical experience with agomelatine and audits physician adherence to EMA recommendations. A retrospective review of patients attending general adult psychiatry services in Carlow /Kilkenny (catchment population 120,000) over one year was performed. 62 patients were prescribed agomelatine. 32 patients (52%) had unipolar depression, and 43 (73%) were already established on antidepressant medication. 60 patients (97%) had LFTs measured before starting treatment with agomelatine, but half of patients (47%) did not have further LFTs as recommended. To increase adherence to EMA recommendations and ensure optimal patient safety, existing barriers to effective monitoring must be addressed.en_GB
dc.language.isoenen
dc.publisherIrish Medical Journalen_GB
dc.subjectPSYCHIATRYen_GB
dc.subjectMENTAL HEALTHen_GB
dc.subjectMEDICATION MANAGEMENTen_GB
dc.subject.otherANTIDEPRESSANTSen_GB
dc.subject.otherAGOMELATINEen_GB
dc.subject.otherMEDICATION ADHERENCEen_GB
dc.titleAgomelatine: Clinical experience and adherence to EMAen_GB
dc.typeArticleen
dc.identifier.journalIrish Medical Journalen_GB
dc.description.provinceLeinsteren
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.